Background: The current study is a randomized, open-label, two-period, two-sequence, two-way crossover pharmacokinetic study in healthy Jordanian subjects to evaluate the pharmacokinetics and bioequivalence profile of two formulations of empagliflozin 10-mg under fasting and fed conditions administered orally.; (2) Methods: The plasma concentrations of empagliflozin were determined using High-performance liquid chromatography- Mass Spectrometry/ Mass Spectrometry (HPLC-MS/MS) method. This study included 26 subjects, 26 in each fasting and fed group.

Inclusion Criteria:

Inclusion Criteria:

• healthy
• Jordanian volunteers
• some private hospitals (Amman, Jordan) Phase I Clinical Unit

Exclusion Criteria:

• Smokers
• heavy drinkers
• those who used CYP enzyme inhibitors within the previous 60 days
• those who had taken any medicine within the previous four weeks
• those who had a history of medication allergies
• those who had participated in previous clinical studies within the previous six months
• those with any significant clinical abnormality